Aditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022
September 13 2022 - 4:15PM
Business Wire
Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company
developing and commercializing technologies focused on monitoring
and modulating the immune system, announced today that it will
effect a 1-for-50 reverse split of its common stock effective as of
4:01 p.m. Eastern Time on September 13, 2022. Commencing with the
opening of trading on The Nasdaq Capital Market on September 14,
2022, the Company’s common stock will trade on a post-split basis
under the same symbol ADTX. The reverse stock split was approved by
the Company’s stockholders at the special meeting held on September
7, 2022, with the final ratio determined by the Company’s board of
directors.
As a result of the reverse stock split, the CUSIP number for the
Company’s common stock will now be 007025505. As a result of the
reverse stock split, every 50 shares of issued and outstanding
common stock will be exchanged for 1 share of common stock, with
any fractional shares being rounded up to the next higher whole
share. Immediately after the reverse stock split becomes effective,
the Company will have approximately 1,156,674 shares of common
stock issued and outstanding.
The reverse stock split is primarily intended to bring the
Company into compliance with Nasdaq’s $1.00 per share minimum bid
price requirement for continued listing.
Additional information concerning the reverse stock split can be
found in Aditxt’s definitive proxy statement filed with the
Securities and Exchange Commission on August 1, 2022, as
amended.
About Aditxt, Inc.
Aditxt is a biotech innovation company developing and
commercializing technologies focused on monitoring and modulating
the immune system. Aditxt’s immune monitoring technologies are
designed to provide a personalized immune profile. Aditxt’s immune
modulating technologies, currently preclinical, are being developed
to retrain the immune system to induce tolerance to address
rejection of transplanted organs, autoimmune diseases and
allergies. For more information, please visit www.Aditxt.com and
www.AditxtScore.com
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220913006253/en/
Media and Investor Relations Contact: ir@aditxt.com
www.aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Apr 2023 to Apr 2024